000			01783 am a22002173u 4500
042			_adc
100	1	0	_aRodriguez-Rodriguez, Noe _eauthor
700	1	0	_aGogoi, Mayuri _eauthor
700	1	0	_aMcKenzie, Andrew N.J. _eauthor _91968
245	0	0	_aILC2s: team players in regulating asthma
260			_c2021-04-26.
500			_a/pmc/articles/PMC7614118/
500			_a/pubmed/33534604
520			_aType-2 immunity helps protect the host from infection, but also plays key roles in tissue homeostasis, metabolism and repair. Unfortunately, inappropriate type-2 immune reactions may lead to allergy and asthma. Group-2 innate lymphoid cells (ILC2s) in the lungs respond rapidly to local environmental cues, such as the release of epithelium-derived type-2 initiator cytokines/alarmins, producing type-2 effector cytokines such as IL-4, IL-5 and IL-13 in response to tissue damage and infection. ILC2s are associated with the severity of allergic asthma and experimental models of lung inflammation have shown how they act as playmakers, receiving signals variously from stromal and immune cells as well as the nervous system, and then disseminating cytokine cues to elicit effector functions and potentiate CD4+ T helper cell activation that characterise the pathology of allergic asthma. Recent breakthroughs identifying stromal and neuronal-derived microenvironmental cues that regulate ILC2s, along with studies recognizing the potential plasticity of ILC2s, have improved our understanding of the immunoregulation of asthma and opened new avenues for drug discovery.
540			_a
546			_aen
690			_aArticle
655	7		_aText _2local
786	0		_nAnnu Rev Immunol
856	4	1	_uhttp://dx.doi.org/10.1146/annurev-immunol-110119-091711 _zConnect to this object online.
999			_c2321 _d2321